CLYM PT raised by Baird; maintained Outperform
Baird maintained an Outperform rating on Clym Bio and raised its price target to $25.00 per share from $21.00, per TradingView News/Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.